SLC2A1 and gastrointestinal stromal tumor: Following low‐dose imatinib treatment, GLUT‐1 levels in GIST cells decrease in a dose‐dependent manner, while GLUT‐1 levels in imatinib‐resistant cells increase proportionally with the dose.